Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.72 USD
Change Today -0.03 / -4.00%
Volume 1.0M
RNN On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (RNN) Snapshot

Open
$0.76
Previous Close
$0.75
Day High
$0.76
Day Low
$0.72
52 Week High
06/12/14 - $1.04
52 Week Low
11/17/14 - $0.65
Market Cap
129.3M
Average Volume 10 Days
829.6K
EPS TTM
$-0.04
Shares Outstanding
179.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REXAHN PHARMACEUTICALS INC (RNN)

Related News

No related news articles were found.

rexahn pharmaceuticals inc (RNN) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (RNN) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer and other medical needs. The company has three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

22 Employees
Last Reported Date: 03/16/15

rexahn pharmaceuticals inc (RNN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $519.0K
President and Chief Operating Officer
Total Annual Compensation: $250.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $338.1K
Compensation as of Fiscal Year 2014.

rexahn pharmaceuticals inc (RNN) Key Developments

Rexahn Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015; Provides an Update of its Three Clinical Development Programs

Rexahn Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2015. The company loss from operations was $4.4 million and $2.8 million for the three months ended March 31, 2015 and 2014, respectively. The company's net loss was $4.3 million, or $0.02 per share, for the three months ended March 31, 2015, compared to a net loss of $14.6 million, or $0.09 per share, for the three months ended March 31, 2014. Included in the net loss for the three months ended March 31, 2015 and 2014 is an unrealized gain (loss) on the fair value of warrants of $0.1 million and $11.7 million, respectively. The fair value adjustments are primarily a result of the changes in the stock price between reporting periods. Cash and investments totaled $29.4 million as of March 31, 2015, compared to $32.7 million as of December 31, 2014. The decrease of $3.3 million was primarily due to $4.0 million of cash used in operating activities, offset by $0.7 million in proceeds received from the exercise of stock options. The company expects that its cash and investments as of March 31, 2015 will be sufficient to fund the company's cash flow requirements for its current activities into the second half of 2016. The company provided an update of its three clinical development programs. Supinoxin (RX-5902): An ongoing Phase I dose-escalation clinical trial of Supinoxin is designed to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) in cancer patients with solid tumors. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. Patients in seven dose groups (25, 50, 100, 150, 225, 300 and 425 mg) have been enrolled, and the MTD has not yet been reached. Depending upon the number of dose groups needed to determine the MTD, Rexahn expects to complete this trial in the first half of 2015. Supinoxin continues to preliminary demonstrate safety and tolerability, requiring higher dose levels than expected to achieve the MTD. RX-3117: An ongoing Phase Ib dose-escalation clinical trial of RX-3117 is designed to evaluate the safety, tolerability, dose-limiting toxicities and MTD in cancer patients with solid tumors. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of RX-3117. Patient enrollment has been completed in eight dose groups (30, 60, 100, 150, 200, 500, 1,000 and 1,500 mg). The MTD of RX-3117 has not yet been achieved. Rexahn expects to complete this trial in the first half of 2015. RX-3117 continues to preliminary demonstrate safety and tolerability, requiring higher dose levels than expected to be tested to achieve the MTD. To date, no dose-limiting toxicities have been associated with RX-3117 treatment. Archexin: The Phase IIa proof-of-concept clinical trial of Archexin in metastatic renal cell carcinoma (RCC) patients is ongoing. The first stage of this study is dose ranging, with up to three dose groups with three RCC patients each, to determine the MTD of Archexin in combination with everolimus, an FDA approved drug for the treatment of RCC. Patient enrollment is ongoing. Rexahn has orphan drug designation for this indication.

Rexahn Pharmaceuticals, Inc. Presents Preclinical Data on Supinoxin™ (RX-5902)

Rexahn Pharmaceuticals, Inc. announced that it presented preclinical data on Supinoxin™ (RX-5902) at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. This presentation entitled, 'Targeting localization and function of the RNA helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)' was co-authored by Frances Fuller-Pace Ph.D., Division of Cancer Research, University of Dundee, United Kingdom and Rexahn scientists. In the present study, Supinoxin™ (RX-5902) was shown to dose-dependently decrease the migration of human triple negative breast cancer cells (MDA-MB-231) in a preclinical model of cancer cell metastasis. Supinoxin is currently in a Phase I dose-escalation clinical trial in cancer patients with solid tumors with clinical data expected in the first half of 2015. Supinoxin™ (RX-5902) is an orally administered, potential first-in-class, small molecule inhibitor of phosphorylated-p68 (P-p68). P-p68, which is selectively overexpressed in cancer cells and is absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of phosphorylated-p68 has been observed in solid tumors, such as melanoma, colon, ovarian and lung tumors. In preclinical studies, Supinoxin has been shown to inhibit proliferation of cells in 18 human cancer cell lines including breast, colon, pancreas, ovarian, and stomach cancers, and showed potent activity in drug-resistant cancer cells. In preclinical animal model, where human cancer cells from melanoma, pancreas, renal or ovarian tumors were grafted into animals, treatment with Supinoxin resulted in a significant reduction in tumor growth. Supinoxin is undergoing a Phase I dose-escalation clinical trial in cancer patients with solid tumors designed to evaluate the safety, tolerability, dose-limiting toxicities and maximal tolerated dose (MTD). Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. This trial is being conducted at 3 clinical oncology centers in the United States. Each patient has the ability to continue on the drug up to six cycles of treatment (a dosing cycle is defined as 3 weeks of drug treatment followed by 1 week off) if no disease progression is seen. Patients are assessed by CT or MRI prior to the start of therapy and after every two cycles of therapy to assess tumor progression. The decision to escalate dose is made after completion of one cycle of treatment based on safety and tolerability. Patients have the possibility to receive up to 6 cycles of treatment if the disease does not progress. Tumor biopsy samples are taken to assess the biomarker phosphorylated-p68. Patients in seven dose groups (25, 50, 100, 150, 225, 300 and 425 mg) have been enrolled, and the MTD has not yet been reached. In preliminary pharmacokinetic data, Supinoxin has approximately 51% oral bioavailability. The ongoing Phase I clinical trial is expected to be completed in the first half of 2015 once the MTD has been achieved.

Rexahn Pharmaceuticals, Inc. Presents Preclinical Data on RX-3117 at the 2015 American Association for Cancer Research Annual Meeting

Rexahn Pharmaceuticals, Inc. presented preclinical data on RX-3117 at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. The presentation is entitled "Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2 (UCK2), a potential biomarker," and is co-authored by Dr. G.J. Peters of the VU University Medical Center, Amsterdam, The Netherlands, and Rexahn scientists. The present study demonstrates a correlation between the expression and enzymatic activity of UCK2 (the enzyme responsible for activating/phosphorylating RX-3117) and the ability of RX-3117 to inhibit the growth of various human cancer cells. These data are important because they further confirm RX-3117's cancer cell specific mechanism of action and the study further suggests that UCK2 expression can be used as a potential biomarker for patient selection into RX-3117 clinical trials. RX-3117 is currently in a Phase Ib clinical trial in cancer patients with solid tumors with clinical data expected in the first half of 2015. RX-3117 is a novel small molecule anti-metabolite compound that once activated (phosphorylated) by UCK2 is incorporated into DNA or RNA of cells and inhibits both DNA and RNA synthesis which induces apoptotic cell death of tumor cells. UCK2 is overexpressed in various human cancer cells. RX-3117 also mediates the downregulation of DNA methyltransferase 1 (DNMT1), an enzyme responsible for the methylation of cytosine residues on newly synthesized DNA and also a target for anticancer therapies. Preclinical studies have shown RX-3117 to be effective in both inhibiting the growth of various human cancer xenograft models, including colon, lung, renal and pancreas, as well as gemcitabine resistant cancer cells.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.72 USD -0.03

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies
 

Industry Analysis

RNN

Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.